Value-based decision-making for orphan drugs with multiple criteria decision analysis: burosumab for the treatment of X-linked hypophosphatemia

Conclusions: MCDA represents a powerful tool in HTA decision-making for OMPs. The results of this MCDA acknowledge burosumab as a disease-modifying drug, deemed superior to conventional therapy for the treatment of paediatric XLH.PMID:33733971 | DOI:10.1080/03007995.2021.1904861

Source: Current Medical Research and Opinion - March 18, 2021 Category: Research Authors: Bj örn Vandewalle Miguel Amorim Diogo Ramos Sofia Azevedo In ês Alves Telma Francisco Helena Pinto S érgio Sousa Source Type: research